Compound Profile
KPV is reviewed here for tissue repair and recovery.
Research Summary
Safety notices, literature searches, limited protocol data
Tissue repair, Injury recovery, Gut support
Target context: Alpha-MSH
Limited, unclear, or affected by safety flags.
Claims need extra caution because evidence is thin or safety flags apply.
Route(s)
Subcutaneous
Typical dose
200mcg - 500mcg
Dosing window
Anytime
Receptor / target
Alpha-MSH
Properties
Not listed
Pre-mixed
No
How KPV is studied in skin inflammation
This skin-focused view shows where KPV is discussed in inflammation and irritation research.
Cheeks — Redness and Irritation
Inflammation researchStudied for inflammatory signals linked to irritated skin.
Face and Neck — Skin Inflammation
Preclinical and mechanistic researchStudied for its possible role in calming inflammatory responses.
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-6 | 200mcg - 500mcg daily | Standard protocol for systemic inflammation or gut repair. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Alternative Titration 1
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 200 mcg 1x Daily | |
| Week 2 | 300 mcg 1x Daily | |
| Week 3 | 400 mcg 1x Daily | |
| Weeks 4-8 | 500 mcg 1x Daily |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 2: Injury Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 500 mcg 2-3x Daily | Administer at or near the injury or inflammation site. |
Alternative research-context example; not an approved-label regimen unless marked above.
Protocol logic check
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | FDA safety-risk context or unapproved compounded-use warning is attached to this entry; no FDA-approved human label was identified for this compound/page context. |
|---|---|
| Where studied | Studied mainly in wound, tendon, ligament, gut, inflammation, angiogenesis, and tissue-repair models; human evidence varies widely by compound. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: Alpha-MSH. Route(s): Subcutaneous. Dosing window on page: Anytime. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: FDA safety-risk context plus missing approved-label dosing; published mechanisms do not remove compounding, purity, sterility, or human-safety uncertainty. |
Source-linked findings
- Repair claims often come from animal, cell, tendon, gut, and angiogenesis models; those models can explain mechanisms but do not prove human recovery protocols.
- Rehab, diagnosis, infection control, vascular risk, anticoagulants, and malignancy history can change the safety interpretation.
- FDA states it has not identified human exposure data for KPV administered by any route.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Weeks 1-6, 200mcg - 500mcg daily; Alternative Titration 1: Week 1, 200 mcg 1x Daily.
- Key limitation: FDA safety-risk context plus missing approved-label dosing; published mechanisms do not remove compounding, purity, sterility, or human-safety uncertainty.
- Monitor injury diagnosis, rehab loading, infection, anticoagulant use, abnormal vessel growth, cancer history, and injection-site sterility.
Selected medical sources
Independent evidence
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Known hypersensitivity to KPV, alpha-MSH-derived peptides, or any formulation excipients.
- Concurrent use of immunosuppressive biologic agents (TNF-alpha inhibitors, IL-6 inhibitors, JAK inhibitors): additive anti-inflammatory pathway inhibition may push the immune response below the threshold needed for pathogen defense; theoretical but warrants clinical consideration.
- Concurrent corticosteroid use: overlapping NF-kB suppression; the additive anti-inflammatory effect may mask warning signs of infection or worsen immune suppression.
- Active infections requiring a robust acute immune response: KPV's NF-kB inhibition, while selective, may blunt cytokine response to active bacterial or viral infections at high doses.
- Pregnancy: no clinical safety data; melanocortin receptor signaling has developmental implications.
- Breastfeeding: no established safety data.
- Pediatric use: safety not established.
- PepT1-negative intestinal conditions: rare congenital PepT1 deficiency would abolish oral/enteric KPV activity.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Mild injection site redness and irritation: the most commonly reported adverse effect; localized erythema at the subcutaneous administration site; transient; self-resolving.
- Mild gastrointestinal discomfort: particularly with oral or higher-dose administration; nausea, loose stools, or abdominal cramping; more common in the first week.
- Temporary fatigue: reported in a minority of subjects; likely related to systemic inflammatory modulation during early treatment.
- Headache: uncommon; transient.
- Skin flushing: rare; mild; may reflect residual melanocortin receptor activity.
- Mild dizziness: infrequent; mechanism unclear.
- Temporary appetite changes: rare; MC4R activity (which KPV may weakly engage) has minor effects on appetite regulation.
- Potential blunting of acute immune response at very high doses: KPV's NF-kB inhibition is dose-dependent; at supraphysiologic doses, the anti-inflammatory effect could theoretically impair the acute phase immune response to active infection.
- Allergic reactions to compounding excipients: redness, hives, stinging at injection site; relates to the compounding vehicle rather than KPV itself.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: